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Obituary
Remembering Marc Leng
th Marc Leng who died on the 7 of May 2000 at the age of 64 from pleural cancer has made an
important contribution in the field of Biophysics. Through years of successful studies on
deoxyribonucleic acids (DNA) and on the mechanism of action ofthe well-known anticancer drug
cisplatin, he gained high international standing and generated more than 200 publications and 3
patents. His death is a great loss for the scientific community as a whole.
Marc was a pure scientist. Honest, direct, he was a man of his word. He was a hard worker and
had a constant intellectual curiosity. Outside scientific matters, he had eclectic tastes from reading
to playing tennis or gardening. He was an expert on wine particularly that coming from his
childhood region.
Marc Leng was born in Bordeaux in the south west ofFrance in 1935, the son ofa medical
doctor. He kept a fond memory, of his childhood and never totally lost his Bordeaux accent. In
1958, he obtained an engineering diploma in chemistry at the Ecole Nationale Sup6rieure de
Chimie in Bordeaux. Being interested in fundamental research and in macromolecules, he started a
PhD in the laboratory of Dr. Benoit at the Centre de Recherche sur les macromol6cules (CRM) in
Strasbourg. That was the start of a successful career in the CNRS. During these years, he entered
the field of polymer chemistry. At the time the CRM had just been created by Pr. Charles Sadron,
the French pioneer of polymers science and of French biophysics. The first scientific task of this
new research centre was to design and construct apparatus enabling precise characterisation of
polymer molecules in dilute solution. Marc’s major interest within this area of research was the use
of light scattering in the study of synthetic polymers. He graduated from the University of
Strasbourg in 1962 and spent the next year and a half fulfillinghis military service commitment in
the Navy. Following this interlude, he moved to the laboratory of Dr. Garry Felsenfeld as a
postdoctoral fellow at the NIH (Bethesda) to pursue his interest in biological macromolecules and
particularly in nucleic acids. He began to study DNA on its own or in interaction with polymers of
lysine and arginine. It was at that point that he began his lifelong scientific adventure n the DNA
world. He discovered that polylysine interacts preferentially with A.T rich DNA. This work was
commented on in Nature (1969), 223, 1101 and was qualified as a remarkable finding. During that
time working together, Dr. Felsenfeld and Marc became close friends, a relationship that would
continue throughout Marc’s life and until his last moments.
In 1966, Marc returned in France and he stayed for one year in the laboratory of Dr. Michelson in
Paris at the Institut de Biologic Physico-chimique where he pursued his research on
polynucleotides. The following year, Charles Sadron founded the Centre de Biophysique
Mol6culaire in Orl6ans and invited Marc to continue his research in this new centre and to lead his
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own team. Very rapidly, he made some major advances. He was the first to show that the ordered
form of polyuridilic acid results from the folding of the molecule on itself through base pairing (the
hairpin model) and this again was commented on in Nature (1970), 227, 22. With great insight,
Marc understood very early that the conformation of macromolecules such as DNA could be as
much a part of the storage of genetic information as the genetic code itself. Later discoveries in
regulation of gene expression proved how right he was. Indeed, today more and more examples
indicate that the plasticity ofDNA conformation plays a key role in the interaction with proteins
and therefore in gene expression.
In 1975, Marc embarked on aproject that was at the time very controversial: the raising of anti-
nucleic acids antibodies. Indeed many grant applications he made on this topic were rejected with
the following comment: anti-nucleic acids antibodies do not exist. Nevertheless, he persevered and
during the next several years, his group worked exclusively on immunisation and the purification
and physico-chemical characterisation of these antibodies. One result of these studies was the
demonstration that antibodies can be useful tools to detect low amounts of chemical modifications
on DNA.
This led Marc to begin studying chemical carcinogenesis, the processes by which normal cells are
transformed into cancer cells. Using antibodies raised against DNA that had been modified by
some carcinogens, he succeeded in quantifying the amount of adducts formed in vivo. In 1983, in
collaboration with the Institut Pasteur (Paris), he used these antibodies to develop a genetic
immunodiagnostic technique that was patented.
The field ofcancer research became a central point in Marc’s research. Around 1980, he
concentrated his efforts on the study ofZ-DNA, the left-handed DNA double helix. He showed that
chemical modification of poly(dG-dC).poly(dG-dC) by some carcinogens induces Z-DNA. This
led him to investigate the existence ofZ-DNA in vivo and its possible implication in cancer. Once
again, his work was of excellence and he was invited to make opening lectures at international
conferences such as the UCLA symposium on Molecular and Cellular Biology at Keystone in
1983.
In 1981, he began his work on the mechanism ofaction of the anticancer drug cisplatin and new
promising platinum based drugs, which was to be his main focus for the next nineteen years. By
generating antibodies against platinated DNA he was able to quantify platinum adducts.
Subsequently, he studied physico-chemical properties of platinated nucleic acids, the interactions
between proteins and platinated DNA and the cross-linking of platinated oligonucleotides to
nucleic acids. In addition to his well-known results on distortions in platinated DNA, he discovered
that a very fine chemistry of some platinum adducts can be promoted by the double helix i) the
formation ofnew adducts between cisplatin and intercalating drugs and their rearrangements ii) the
rearrangement of the transplatin 1,3-ntrastrand cross-links into interstrand cross-links. Recently,
this latter reaction was used to modulate gene expression as part as an antisense strategy which has
been patented. Marc will not be able to pursue this promising research since the very disease he
was trying to find a cure for unfortunately defeated him.
Marc was nationally recognised for his scientific contributions. He was appointed director of
research of the hi.ghest level and had had an important position at the direction of CNRS since
1999. He was co-drector of postgraduate studies in Biologie-Biophysique Mol6culaire et Cellulaire
and lecturer at the University of Orl6ans-Tours. He has been in charge of 30 theses and Marc’s
students left his laboratory with a sense of scientific honesty and determination for the future. He
was the co-ordinator of the Biomed 2 european contract and participated in the european Cost D8
project "Metal in Medicine". He was also an editorial board member of "Metal-Based Drugs"
journal since 1994.
Not everyone’s life is as fulfilled as that ofMarc Leng’s. He had an exceptional career, ajoyous
ma_rriage, three successful children and he was a loving grandfather. Never since I began my theses
with Marc in 1982 did I imagine that his dynamism and his determination could vanish so
suddenly. All members of his team as well as friends and colleagues all over the world will never
forget his memory.
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